StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA by Year

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide reported growth YoY (%) (%)

Johnson & Johnson PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA: -7.7% in FY2025, unchanged from a year earlier. That is the lowest of the 9 years on record here.

Latest, FY2025
-7.7%
Period ended Dec 28, 2025
Change on a year earlier
0.0 pts
-7.7% in FY2024
History
9 years
Since FY2017
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| WW | 1,579 | 1,712 | (7.7) | (8.1) | 0.4”

Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide reported growth YoY (%) (%)Year on yearSource
FY2025Dec 28, 2025-7.7%0.0 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
FY2024Dec 29, 2024-7.7%-3.1 ptsForm 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
FY2023Dec 31, 2023-4.6%+2.1 ptsForm 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗
FY2022Jan 1, 2023-6.7%-2.1 ptsForm 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗
FY2021Jan 2, 2022-4.6%-8.1 ptsForm 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗
FY2020Jan 3, 20213.5%-4.5 ptsForm 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗
FY2019Dec 29, 20198.0%+0.6 ptsForm 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗
FY2018Dec 30, 20187.4%+9.0 ptsForm 8-K (a2018q4exhibit9915.htm, filed 2019-01-22) ↗
FY2017Dec 31, 2017-1.6%–Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗

Cite this data

StockData. (2026). Johnson & Johnson PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (%), annual FY2017–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-prezista-rep-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.